公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 40 | 41 | |
2015 | Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy | Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU ; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. | Clinical Cancer Research | 419 | 382 | |
2013 | Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial | Wu Y.-L.; Lee J.S.; Thongprasert S.; CHONG-JEN YU ; Zhang L.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Sandoval-Tan J.; Zhu Y.; Liao M.; Zhou C.; Pan H.; Lee V.; Chen Y.-M.; Sun Y.; Margono B.; Fuerte F.; Chang G.-C.; Seetalarom K.; Wang J.; Cheng A.; Syahruddin E.; Qian X.; Ho J.; Kurnianda J.; Liu H.E.; Jin K.; Truman M.; Bara I.; Mok T. | The Lancet Oncology | 277 | 247 | |
2016 | Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer | Mok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; CHONG-JEN YU ; Thongprasert S.; Sandoval-Tan J.; Lee J.S.; Fuerte F.; Shames D.S.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.-L. | Lung Cancer | 20 | 18 |